A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome

Javier Delgado-Lista; Pablo Perez-Martinez; Antonio Garcia-Rios; Catherine M. Philliips; Wendy Hall; Ingrid M.F. Gjelstad; Denis Lairon; Wim Saris; Beata Kiec-Wilk; Brita Karlstrom; Christian A. Drevon; Catherine Defoort; Ellen A. Blaak; Aldona Dembinska-Kiec; Ulf Riserus; Julie A Lovegrove; Helen M. Roche; Jose Lopez-Miranda

doi:10.1016/j.numecd.2011.09.008

A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome

Javier Delgado-Lista
, Pablo Perez-Martinez
, Antonio Garcia-Rios
, Catherine M. Philliips
, Wendy Hall
, Ingrid M.F. Gjelstad
, Denis Lairon
, Wim Saris
, Beata Kiec-Wilk
, Brita Karlstrom
, Christian A. Drevon
, Catherine Defoort
, Ellen A. Blaak
, Aldona Dembinska-Kiec
, Ulf Riserus
, Julie A Lovegrove
, Helen M. Roche
, Jose Lopez-Miranda

Nutritional Sciences

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Background and aims:
CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients.

Methods and results:
Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration.

Conclusion:
The presence of the A allele of rs12691 influences glucose metabolism of MetS patients. Clinical Trials Registry number NCT00429195.

Original language	English
Pages (from-to)	417-423
Number of pages	7
Journal	NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Volume	23
Issue number	5
DOIs	https://doi.org/10.1016/j.numecd.2011.09.008
Publication status	Published - May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.numecd.2011.09.008

Cite this

Delgado-Lista, J., Perez-Martinez, P., Garcia-Rios, A., Philliips, C. M., Hall, W., Gjelstad, I. M. F., Lairon, D., Saris, W., Kiec-Wilk, B., Karlstrom, B., Drevon, C. A., Defoort, C., Blaak, E. A., Dembinska-Kiec, A., Riserus, U., Lovegrove, J. A., Roche, H. M., & Lopez-Miranda, J. (2013). A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 23(5), 417-423. https://doi.org/10.1016/j.numecd.2011.09.008

@article{bc89b76ffa2b48febf50139711a2b3ff,

title = "A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome",

abstract = "Background and aims: CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients. Methods and results: Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration. Conclusion: The presence of the A allele of rs12691 influences glucose metabolism of MetS patients. Clinical Trials Registry number NCT00429195.",

author = "Javier Delgado-Lista and Pablo Perez-Martinez and Antonio Garcia-Rios and Philliips, \{Catherine M.\} and Wendy Hall and Gjelstad, \{Ingrid M.F.\} and Denis Lairon and Wim Saris and Beata Kiec-Wilk and Brita Karlstrom and Drevon, \{Christian A.\} and Catherine Defoort and Blaak, \{Ellen A.\} and Aldona Dembinska-Kiec and Ulf Riserus and Lovegrove, \{Julie A\} and Roche, \{Helen M.\} and Jose Lopez-Miranda",

year = "2013",

month = may,

doi = "10.1016/j.numecd.2011.09.008",

language = "English",

volume = "23",

pages = "417--423",

journal = "NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES",

publisher = "Elsevier BV",

number = "5",

}

Delgado-Lista, J, Perez-Martinez, P, Garcia-Rios, A, Philliips, CM, Hall, W, Gjelstad, IMF, Lairon, D, Saris, W, Kiec-Wilk, B, Karlstrom, B, Drevon, CA, Defoort, C, Blaak, EA, Dembinska-Kiec, A, Riserus, U, Lovegrove, JA, Roche, HM & Lopez-Miranda, J 2013, 'A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome', NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, vol. 23, no. 5, pp. 417-423. https://doi.org/10.1016/j.numecd.2011.09.008

TY - JOUR

T1 - A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome

AU - Delgado-Lista, Javier

AU - Perez-Martinez, Pablo

AU - Garcia-Rios, Antonio

AU - Philliips, Catherine M.

AU - Hall, Wendy

AU - Gjelstad, Ingrid M.F.

AU - Lairon, Denis

AU - Saris, Wim

AU - Kiec-Wilk, Beata

AU - Karlstrom, Brita

AU - Drevon, Christian A.

AU - Defoort, Catherine

AU - Blaak, Ellen A.

AU - Dembinska-Kiec, Aldona

AU - Riserus, Ulf

AU - Lovegrove, Julie A

AU - Roche, Helen M.

AU - Lopez-Miranda, Jose

PY - 2013/5

Y1 - 2013/5

N2 - Background and aims: CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients. Methods and results: Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration. Conclusion: The presence of the A allele of rs12691 influences glucose metabolism of MetS patients. Clinical Trials Registry number NCT00429195.

AB - Background and aims: CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients. Methods and results: Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration. Conclusion: The presence of the A allele of rs12691 influences glucose metabolism of MetS patients. Clinical Trials Registry number NCT00429195.

U2 - 10.1016/j.numecd.2011.09.008

DO - 10.1016/j.numecd.2011.09.008

M3 - Article

VL - 23

SP - 417

EP - 423

JO - NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

JF - NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

IS - 5

ER -

A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this